Revelation Biosciences Achieves GMP Milestone for Gemini Drug, Advancing CKD Treatment Development

Revelation Biosciences Achieves Key Manufacturing Milestone for Gemini Drug Product

Revelation Biosciences, Inc. has reached a significant milestone in its development of the Gemini drug product, having completed Good Manufacturing Practice (GMP) compliant manufacturing. This achievement is pivotal as it sets the stage for submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Gemini is an intravenous formulation of phosphorylated hexaacyl disaccharide (PHAD®), designed to enhance the innate immune system's response to various stressors, including trauma and infection. The completion of GMP manufacturing not only facilitates the initiation of a Phase 1b clinical trial for chronic kidney disease (CKD) patients but also lays the groundwork for subsequent Phase 2 studies.

CEO James Rolke expresses optimism regarding the implications of this milestone. He anticipates that top-line results from the upcoming trials, which will include pharmacokinetic, pharmacodynamic, and safety data, will be available in the first half of 2025. The results are expected to validate the promising data gathered from preclinical studies and earlier Phase 1 trials, where Gemini demonstrated significant pharmacodynamic activity and met essential safety endpoints. This optimism is further fueled by the growing body of evidence that supports Gemini's therapeutic potential in mitigating inflammation—a key factor in chronic kidney disease and other inflammatory conditions.

Revelation's strategic focus on leveraging trained immunity is evident in its ongoing programs utilizing Gemini for multiple indications. These include preventing acute kidney injury, reducing the severity of post-surgical infections, and slowing CKD progression. The company's commitment to developing innovative therapies through Gemini underscores its broader mission to advance treatment options for patients suffering from immune-related conditions. As Revelation Biosciences moves closer to clinical testing, the potential impact of Gemini on chronic kidney disease and related health challenges becomes increasingly tangible.

In addition to the manufacturing milestone, Revelation Biosciences continues to emphasize its dedication to research and development. The company aims to explore further applications of Gemini in various medical contexts, reflecting a proactive approach to tackling significant health issues. With ongoing studies and anticipated clinical trials, Revelation is poised to make meaningful contributions to the biopharmaceutical landscape.

As the company progresses toward its clinical goals, stakeholders remain attentive to the developments that could position Revelation Biosciences as a leader in immune-modulating therapies. The successful completion of GMP manufacturing is a crucial step that could pave the way for significant advancements in treating chronic kidney disease and other inflammatory disorders. For more information, Revelation Biosciences invites interested parties to visit its website at www.RevBiosciences.com.